April 2020 Clinical Watch Newsletter

May 21, 2020

In this issue of Clinical Watch, we highlight the NIH Panel recommendations regarding medications associated with COVID-19 treatment and suggest prior authorization criteria for the first approved treatment for erythropoietic protoporphyria. Lastly, we review claims data to identify potential users for a new treatment for heavy menstrual bleeding associated with uterine fibroids.

For more information about a specific topic, please contact Janelle Sheen or Karen Powell. Be sure to stay tuned for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacysolutions.

Previous Flipbook
2018 Customer Experience Report for High Tech
2018 Customer Experience Report for High Tech

Customer expectations have grown exponentially.Companies must deliver seamless, real-time, personalized exp...

Next Flipbook
Conduent Named a Major Contender in Everest Group Report
Conduent Named a Major Contender in Everest Group Report

Conduent emerged as a Major Contender in the PEAK Matrix and Everest Group identified Conduent to have well...